Merrimack takes price cut to raise cash
This article was originally published in Scrip
Executive Summary
With its supply of cash set to run out next year, Merrimack Pharmaceuticals went to market on 11 July with 5 million shares priced at $5 each – $2 below the prior day's closing price – and sold convertible senior notes with an aggregate principal amount totaling $125 million.